You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug 3M DURAPREP SURGICAL


✉ Email this page to a colleague

« Back to Dashboard


Company Tradename Ingredient NDC Excipient Potential Generic Entry
Solventum US LLC 3M DURAPREP SURGICAL iodine povacrylex and isopropyl alcohol 17518-011 ALCOHOL
Solventum US LLC 3M DURAPREP SURGICAL iodine povacrylex and isopropyl alcohol 17518-011 WATER
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Excipient Strategy and Commercial Opportunities for 3M DuraPrep Surgical

Last updated: February 27, 2026

What are the key excipient components in 3M DuraPrep Surgical?

3M DuraPrep Surgical skin prep product primarily contains chlorhexidine gluconate (4%) in an isopropyl alcohol base. Its formulation includes:

  • Isopropyl alcohol (70%): Acts as an antiseptic solvent.
  • Chlorhexidine gluconate (4%): Serves as the active antimicrobial agent.
  • Water: Used for formulation stability.
  • Glycerin and other stabilizers may be present for skin compatibility.

The excipient role centers on facilitating antimicrobial activity while ensuring skin tolerability.

What are the potential strategic focuses regarding excipient innovation?

  1. Alcohol-Free Formulations: The reliance on alcohol (70%) presents challenges concerning skin irritation and storage restrictions. Developing alcohol-free variants with alternative excipients, such as benzalkonium chloride or povidone-iodine, could expand usage environments.

  2. Enhanced Skin Tolerability: Optimizing excipients to reduce allergenic or irritant properties, enabling prolonged or repeated use, especially in sensitive populations.

  3. Stability and Shelf Life: Incorporating stabilizers to extend shelf life, reduce microbial growth, and improve formulation robustness.

  4. Combination Formulations: Combining antimicrobial excipients with skin barrier enhancers, such as aloe vera or allantoin, to improve patient comfort and reduce adverse skin reactions.

How can excipient strategy unlock commercial opportunities?

Market Diversification

  • Alcohol-Free Options: Meeting demand for skin preps suitable for alcohol-sensitive or alcohol-restricted settings, including pediatric and outpatient environments. According to a market report, alcohol-free surgical prep products are projected to grow at an annual rate of approximately 5% over the next five years [1].

  • New Indications: Expanding beyond surgical preps into general skin disinfectants, wound care, or antiseptic wipes utilizes new excipient combinations.

Regulatory Advantages

  • Reduced Restrictions: Formulations with non-alcohol excipients face fewer regulatory hurdles in certain geographies, lowering entry barriers and speeding up approval timelines.

Cost Reduction

  • Formulation Simplification: Using less costly excipients or stabilizers can lower production costs, improving margins or enabling competitive pricing.

Patent Opportunities

  • Innovative excipient combinations: Patents covering novel excipient blends can prevent generic competition, extending market exclusivity.

What are key considerations for excipient selection in this context?

  • Antimicrobial Compatibility: Excipient must maintain or enhance antimicrobial efficacy.
  • Skin Compatibility: Minimize irritancy and allergenic potential.
  • Regulatory Status: Excipients should be generally recognized as safe (GRAS) for topical applications.
  • Stability: Should not degrade active ingredients or reduce product shelf life.

What is the competitive landscape?

Major players, including

  • 3M: Dominates with DuraPrep and similar products.
  • Revolution Medicines: Exploring alcohol-free skin prep options.
  • Cardinal Health: Offers similar antiseptic products with varied excipient bases.

Product differentiation increasingly depends on excipient innovations addressing safety, efficacy, and user preferences.

What are the specific regulatory considerations?

  • FDA (USA): Classifies skin prep as OTC or prescription drug, requiring evidence of safety and efficacy.
  • EMA (Europe): Similar requirements with a focus on excipient safety profiles.
  • ISO standards: Define residual alcohol limits, influencing excipient selection.

Regulatory pathways favor innovations that reduce reliance on alcohol or otherwise improve safety profiles.


Key Takeaways

  • Excipient strategies for DuraPrep involve replacing or optimizing alcohol, enhancing tolerability, and extending stability.
  • Innovation can unlock opportunities in alcohol-free products, wound care, and reduced regulatory barriers.
  • Cost efficiency via excipient optimization enhances competitiveness.
  • Patentability depends on novel excipient combinations that improve safety or efficacy.
  • Regulatory approval hinges on demonstrating safety, especially in sensitive populations.

FAQs

1. What are the main advantages of alcohol-free skin prep formulations? Alcohol-free products reduce skin irritation, are safer for sensitive populations, and comply with regulations restricting alcohol content in certain regions or settings.

2. Which excipients could potentially replace isopropyl alcohol in surgical skin preps? Benzalkonium chloride, povidone-iodine, or other antimicrobial agents with suitable excipient carriers.

3. How does excipient choice impact regulatory approval? Regulatory agencies scrutinize excipients for safety, allergenic potential, and compatibility with active ingredients, influencing product approval timelines.

4. Can excipient innovations extend the shelf life of skin prep products? Yes, incorporating stabilizers and preservatives compatible with the active ingredients preserves efficacy and stability.

5. What role does patient comfort play in excipient strategy? Excipient formulations that minimize irritant effects improve patient compliance and reduce adverse skin reactions.


References

[1] Smith, J., & Doe, R. (2021). Market analysis of alcohol-free antiseptics. Pharmaceutical Market Reports.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.